Edwards Lifesciences Corp. (NYSE:EW) had its price objective hoisted by Citigroup Inc. from $86.00 to $94.00 in a note issued to investors on Wednesday. The brokerage currently has a “sell” rating on the medical research company’s stock. Citigroup Inc.’s price target suggests a potential downside of 21.52% from the company’s current price. Several other equities […]
